Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

36 results about "Immunoglobulins / Antibodies" patented technology

Immunoglobulins (Antibodies) are proteins that are found in blood or other bodily fluids of vertebrates, and are used by the immune system to identify and neutralize foreign objects, such as bacteria and viruses.

Method of detecting surrogate markers in a serum sample

The invention provides a method of detecting surrogate markers for active tuberculosis in a serum sample. The surrogate markers are selected from serum mycolic acid antigen, serum anti-mycolic acid antibodies or both. The method includes the steps of combining the serum sample with a labelled monoclonal immunoglobulin antibody or fragment thereof to mycolic acids to produce a combined serum sample, the antibody or fragment thereof not substantially cross-reacting with cholesterol and the label being selected so that binding of the labelled antibody to immobilized mycolic acid antigen of mycobacterial origin produces a detectable signal and combining a blank sample with the labelled monoclonal immunoglobulin antibody or fragment thereof to mycolic acid to produce a combined blank sample. The method includes exposing both samples to immobilised mycolic acid antigen of mycobacterial origin or a synthetic analogue or analogues thereof so that the labelled immunoglobulin antibodies or fragments thereof in each sample bind to the immobilised antigen to produce detectable signals. If the surrogate markers are present, the signal produced by the blank sample will be stronger than that produced by the serum sample because of inhibition of binding of the labelled antibody in the serum sample arising from prior binding of the labelled antibody with the mycolic acid antigen in the serum sample or by competitive binding of serum anti-mycolic acid antibodies in the serum sample to the immobilised mycolic acid antigen or both.
Owner:UNIVERSITY OF PRETORIA

Quick detection method for newcastle disease virus and its immune colloidal gold test card

The invention provides a method for quickly detecting Newcastle disease virus. The method comprises the following steps that: a Newcastle disease virus monoclonal antibody, a goat-anti-Newcastle disease virus polyclonal antibody and a goat-anti-Balb/C mouse immunoglobulin antibody are established; the treatment of a combination pad and NC membrane is completed; after a to-be-detected sample is added on a sample pad and filtered, the NDV in the sample is combined with the gold-labeled antibody in the combination pad; the gold-labeled antibody is firstly combined with the Ab2 on the NC membrane through chromatography to form a visible combining line, and an uncombined gold-labeled antibody undergoes chromatography continuously and is combined with Ab3 to form a second combining line; finally, a step of result observation, during which, two combining lines are formed when the result is positive, while one quality control line is formed when the result is negative. The method has the characteristics of simple operation, quickness, high sensitivity and excellent specificity, etc.; moreover, the method is low in cost and is suitable for Newcastle disease virus detection at grass root or clinic; in addition, the method can detect the Newcastle disease virus in bird blood and dejection and can obtain a result within 10 min with the sensitivity reaching to 10ng/ml. The invention also provides a Newcastle disease immune colloidal gold test card for realizing the method.
Owner:CHONGQING UNIV OF TECH

Method for preparing anti-A type botulinus toxin immunoglobulin antibody

The invention discloses a method for preparing an anti-type A botulinum neurotoxin immunoglobulin antibody, which comprises the steps of preparing and obtaining the anti-type A botulinum neurotoxin immunoglobulin antibody through taking type A botulinum neurotoxin recombinant protein rAHc as immunogen to immunize animals. The method for preparing the anti-type A botulinum neurotoxin immunoglobulin antibody eliminates a Fc segment in the antibody which can cause side effect and obtains the horse anti-type A botulinum neurotoxin immunoglobulin F(ab')2 antibody; after blood serum obtained by pentalogy hyper-immune and hexalogy hyper-immune are mixed, the content (purity) of F(ab')2 of the antibody can achieve 80.2 percent in a semi-finished product obtained through further purification; the titer of the antibody can achieve 8000 IU / ml; the antibody has good specificity and sensitivity to type A botulinum neurotoxin; and the purity and the specific activity of the antibody are higher than the antitoxin prepared from the traditional toxin immunity horses. Moreover, the invention has the good stability and safety.
Owner:INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE

Immunologic assay for detection of autoantibodies to folate binding protein

InactiveUS20060115860A1Improve processingDisease diagnosisBiological testingFolate-binding proteinFluorescence
The present invention is directed to an assay that detects autoantibodies to folate receptor and can be used in the clinical diagnostic testing of these autoantibodies in humans. Although there are other methods that exist to detect these autoantibodies, the assay described in the present invention has several features that offer advantages over the existing methods. Some of these features include adaptability to high-throughput processing, the use of an immunoglobulin antibody to bind autoantibodies bound to folate receptor or the use of enzyme-labeled folic acid to bind folate binding protein and use of fluorescence or chemiluminescence for detection. This assay thereby avoids the use of radioactivity and can be automated and scaled to process hundreds of samples safely and simultaneously.
Owner:CABRERA ROBERT M +1

Applications of NY-ESO-1 as molecule adjuvant in enhancement of Art v1 (wtArt) allergen immune reaction

The present invention relates to the field of biomedicine, particularly to applications of NY-ESO-1 as a molecule adjuvant in enhancement of an Art v1 (wtArt) allergen immune reaction. According to the present invention, it is explored that the NY-ESO-1 protein can form a poly-structure even in a loading buffer containing beta-mercaptoethanol having a conventional concentration, the polymerization reaction of the NY-ESO-1 is mediated by the intermolecular disulfide bond, the binding of the NY-ESO-1 and the human/murine immature dendritic cells in vitro is related to the polymerization structure of the NY-ESO-1, TLR4 affects the in vitro binding of the NY-ESO-1 and the DC cells in bone marrow, the binding of the NY-ESO-1 and the human/murine immature dendritic cells can be performed through the action of calreticulin, the polymer oligomerization reduces the binding of TLR4 and NY-ESO-1, the polymer structure of the NY-ESO-1 and TLR4 in host participate into an immunoglobulin antibody reaction, and the improving of the art V1 (wtArt) and CA9 gene immunogenicity depends on the NY-ESO-1 gene fusion expression; and the test results prove that the NY-ESO-1 can be adopted as the molecule adjuvant in enhancement of the Art v1 (wtArt) allergen immune reaction.
Owner:宁波美丽人生医药生物科技发展有限公司

Preparation method of cTnI, NT-proBNP and D-dimer chest pain triple colloidal gold immunostrip

The invention relates to a preparation method of a cTnI, NT-proBNP and D-dimer chest pain triple colloidal gold immunostrip. The detection problem of cTnI, NT-proBNP and D-dimer can be effectively solved. The preparation method comprises the following steps: respectively preparing an anti-cTnI protein conjugate monoclonal antibody, an anti-NT-proBNP protein conjugate monoclonal antibody and an anti-D-dimer protein conjugate monoclonal antibody for colloidal gold marking and a coating detection line; respectively preparing colloidal gold markers of the anti-cTnI protein conjugate monoclonal antibody, the anti-NT-proBNP protein conjugate monoclonal antibody and the anti-D-dimer protein conjugate monoclonal antibody, drying and curing the colloidal gold markers, sequentially coating the anti-cTnI protein conjugate monoclonal antibody, the anti-NT-proBNP protein conjugate monoclonal antibody and the anti-D-dimer protein conjugate monoclonal antibody for the coating detection line on a nitrocellulose membrane from left to right to form a detection line, and coating an anti-mouse immunoglobulin antibody on the nitrocellulose membrane to form a quality control line of the coating membraneso as to prepare the cTnI, NT-proBNP and D-dimer chest pain triple colloidal gold immunostrip. The preparation method provided by the invention is simple in process and is novel and unique, and various acute chest pains can be diagnosed and identified quickly, conveniently and effectively at the early stage.
Owner:HENAN ACAD OF SCI INST OF BIOLOGY LIABILITY

Bovine immunoglobulin (IgG) double-antibody sandwich colloidal gold immunochromatographic test strip, preparation method, kit and detection method

The invention provides a bovine immunoglobulin (IgG) double-antibody sandwich colloidal gold immunochromatographic test strip, a preparation method, a kit and a detection method. The colloidal gold immunochromatography test strip is characterized by comprising a bottom plate, and a water absorption pad, a chromatographic membrane, a conjugate release pad and a sample pad which are arranged on thePVC bottom plate in an overlapping manner. The conjugate release pad is coated with a colloidal gold labeled bovine immunoglobulin antibody a compound, the chromatographic membrane is provided with adetection line and a quality control line, the detection line is coated with an anti-bovine immunoglobulin antibody b, and the quality control line is coated with goat anti-mouse IgG. The invention also provides a preparation method of the chromatographic test strip, a kit comprising the reagent strip, and a detection method of the kit. According to the technical scheme, the kit is prepared basedon the principles of double-antibody sandwich colloidal gold color development and gold-labeled immunoassay analyzer quantification, and can be used for rapidly and quantitatively detecting the content of bovine immunoglobulin (IgG).
Owner:HANGZHOU BINGUO INFORMATION TECH CO LTD

In-vitro binding of immature dendritic cells mediated by NY-ESO-1 via polymeric structure domain

The invention relates to the field of biological medicine, in particular to in-vitro binding of immature dendritic cells mediated by NY-ESO-1 via a polymeric structure domain. The inventor of the invention discovers that NY-ESO-1 protein can form a poly structure even in a loading buffer with the conventional concentration of beta-mercaptoethanol; a polymerization reaction of NY-ESO-1 is mediated by an intermolecular sulfide bond of NY-ESO-1; the in-vitro binding of NY-ESO-1 with the immature human and mouse dendritic cells is related to a polymerization structure of NY-ESO-1; TLR4 influences in-vitro binding of NY-ESO-1 with DCs in marrow; the binding of NY-ESO-1 with the immature human and mouse dendritic cells can also be achieved by a calprotectin effect; the oligomerization of a polymer reduces the binding capacity of TLR4 and NY-ESO-1; a polymer structure of NY-ESO-1 and TLR4 in a host participate in immunoglobulin antibody response; and Art v1 (wtArt) and CA9 gene immunogenicity is improved by NY-ESO-1 gene fusion expression. NY-ESO-1 is confirmed to mediate the in-vitro binding of the immature dendritic cells via the polymeric structure domain.
Owner:宁波美丽人生医药生物科技发展有限公司

Test strip with structured substrate for multiplex lateral flow assay for disease diagnostics

Methods and kits for diagnosis of confirmatory diagnosis of a tick-borne infection, such as Lyme disease, is provided. The methods and kits include one or more multi-channel lateral flow immunoassay test strips. In an embodiment, the test strip comprises at least five individual, discrete fluid flow channels where each of the at least five channels includes one or more binding members (antigens) for detection of immunoglobulin antibodies against a Borrelia bacterium in a blood sample. The binding members (antigens) are, in one embodiment, selected from a group of immunoglobulin antibodies consisting of p18 (decorin-binding protein), p23, p28, p30, p39, p41 (flagellin), p45, p58, p66, p93, VlSE / C6 and p31. The kits include external controls selected from a container with a positive control, a container with a negative control, and both of a container with a positive control and a container with a negative control.
Owner:QUIDEL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products